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Background. The potential available market (PAM) for new diagnostics for tuberculosis that meet the speciﬁ-
cations of the high-priority target product proﬁles (TPPs) is currently unknown.
Methods. We estimated the PAM in 2020 in 4 high-burden countries (South Africa, Brazil, China, and India) for
tests that meet the speciﬁcations outlined in the TPPs. The yearly PAM was estimated for the most likely application
of each TPP.
Results. In 2020 the PAM for all 4 countries together was estimated to be (1) 12M tests/year with a value of 48M-
71M USD for a sputum smear-replacement test; (2) 16M tests/year with a value of 65M–97M USD for a biomarker
test; (3) 18M tests/year with a value of 18M–35M USD for a triage test; (4) 12M tests/year with a value of 59M–
2238M USD for a tuberculosis detection plus drug susceptibility test (DST) all-in-one or 1.5M tests/year for a
DST that follows a positive tuberculosis detection test with a corresponding value of 75M–121M for both tubercu-
losis detection and DST.
Conclusions. Although there is a considerable potential market for novel tuberculosis diagnostics that ﬁt the
speciﬁcation of the TPPs in the 4 high-burden countries, the actual market for an individual product remains
uncertain.
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Recently the World Health Assembly adopted the post-
2015 global tuberculosis strategy setting the target for a
world free of tuberculosis [1].
Without the introduction of new tools that can cause a
more rapid decline in tuberculosis incidence than the cur-
rent global decline of 2% per year, it is obvious that the
post-2015 targets will not be achieved. The development
and implementation of new tools and interventions, such
as a more effective tuberculosis vaccine, and tuberculosis
treatment regimens or more accurate diagnostics that
reach more patients are therefore urgently needed.
Recently the tuberculosis community identiﬁed the
highest needs for new tuberculosis diagnostics [2, 3].
Four of these detailed target product proﬁles (TPPs)
were developed, and the tuberculosis community reached
consensus on the most important speciﬁcations laid out
in each of these TPPs [4, 5]. The 4 TPPs, described in de-
tail elsewhere in this supplement [4] included (1) A point
of care sputum-based test as a replacement for smear-
microscopy (‘smear replacement test’); (2) A point of
care, non-sputum-based test capable of detecting all
forms of tuberculosis via the identiﬁcation of characteris-
tic biomarkers or biosignatures, ideally suitable for use at
levels below microscopy centers (“non-sputum based bi-
omarker test”); (3) A simple, low cost, point of care triage
test, for use by ﬁrst-contact health care providers as a
rule-out test, ideally suitable for use by community
health workers (“triage test”); and (4) A rapid drug sus-
ceptibility test (DST) that either combines tuberculosis
detection and DST into one step (“tuberculosis detection
plus DST upfront”) or performs tuberculosis detection
ﬁrst and is followed by DST as a second step whenever
tuberculosis (or tuberculosis and rifampicin resistance)
is detected (“DST after tuberculosis detection test”).
Test developers have indicated that apart from clearly
speciﬁed product requirements, key drivers for them to
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start or continue product development are the time to return on
investment, the global market size, the market size on a country
level, and the market dynamics [6].
Thus far, several analyses of the tuberculosis diagnostic market
have been done, either on a global level or on a country level [7–
9]. The tuberculosis diagnostic market has been determined for
South Africa and Brazil, and others are underway for China
and India [7,9]. Those assessments focused on the current, served
available market of existing tuberculosis diagnostics and did not
make any inferences on the potential market of novel tests that
target other (new) populations now or in the near future.
In this article, we estimate the potential available market
(PAM) for the 4 novel high-priority tests, for which TPPs are
in place. This market is described for 4 high-burden countries,
being South Africa, Brazil, China, and India, which are part of
the BRICS countries (including Russia). The BRICS countries
amount to 60% of the total burden of tuberculosis in the 22
high-burden countries and therefore are of special interest for
test developers and for tuberculosis control.
METHODS
The potential market in 2020 was estimated both in terms of
volume and value for the following 4 selected countries; South
Africa, Brazil, China, and India. These countries are emerging
economies that are of interest for test manufacturers and have a
high tuberculosis burden (they account for 46% of the 6 million
tuberculosis cases detected in 2012). The potential market value
was calculated bymultiplying the projected volume for each of the
tests by its lowest and highest price as indicated in the TPP. How-
ever, the prices indicated in the TPP are ex-works costs which in-
clude the manufacturers’ price but do not include any costs
related to shipping, import, tax, and distribution. Because there
was no consensus reached on the price of the rapid DST TPP,
we assumed that the price of the “tuberculosis detection plus
DST upfront test” would lie in the range of US$5 to US$20 per
test, similar to what was assumed by Pantoja et al [10]. When
DST would only follow a positive tuberculosis detection (or
rifampicin resistant) test, we assumed that the price of the tuber-
culosis detection test would be similar to that of a sputum smear-
replacement test outlined in TPP 1 (US$5) and that the price of
the DST would be between US$10 and US$40 (corresponding
with a total of US$15–US$45 for tuberculosis detection andDST).
Using country-speciﬁc notiﬁcation data and prevalence esti-
mates [11], we ﬁrst determined the potential market per country
for each of the TPPs for the year 2012 as a base. For each country,
the proportion of tuberculosis patients with pulmonary tuber-
culosis (PTB), extrapulmonary tuberculosis (EPTB), and children
with tuberculosis (assumed to be unable to provide a sputum
sample and therefore not included in the number of PTB pa-
tients), were estimated separately. Next, the number of prevalent
tuberculosis patients in 2012 in each of these categories was
determined, using the World Health Organization’s (WHO) es-
timated prevalence data.
To calculate the number of individuals with signs and symp-
toms suggestive of tuberculosis that need to be tested to ﬁnd all
prevalent tuberculosis, we applied a country speciﬁc “suspect-
to-case” ratio, deﬁned as the number of individuals that is
being tested in order to ﬁnd 1 tuberculosis case. For each of the
countries this ratio was calculated based on PTB cases and was
then extrapolated to other non-PTB cases due to lack of infor-
mation for the latter. This ratio was either determined based on
country speciﬁc data on the number of individuals that were
screened in 2012 with smear (and/or the Xpert MTB/RIF®
assay “Xpert”) as the initial test (South Africa and India) or
number of smears done for the initials diagnosis (China and
Brazil) and the number of notiﬁed PTB cases in 2012 dependent
on the availability of data.
Because no novel tests that meets the speciﬁcation outlined in
the TPPs is on the market yet, but tests are anticipated to be-
come available within the next 5 years, we estimated the poten-
tial market for each of the novel products for the year 2020. The
number of prevalent tuberculosis cases in 2020 was estimated
based on the 3-year average decline in the tuberculosis preva-
lence rate and multiplied by the expected population size in
2020 according to the World Bank [12].
For each TPP, the potential market of the base case scenario
represented the most likely use of the test with regard to where
in the health-care system it would be implemented and its pur-
pose and intended target population (eg, adults and children
suspected of PTB, EPTB). In addition, the potential market
was determined for alternative scenarios where the test would,
for instance:
1. be used on more or less individuals with presumptive tu-
berculosis than the current estimate by assuming a lower or
higher “suspect-to-case” ratio (applicable for all tests but
shown for the smear replacement test);
2. be deployed at a lower level of the health-care system and
therefore reach a larger population (applicable for the bio-
marker and triage test); or
3. only be able to test a subset of the intended target popu-
lation (applicable for the biomarker test or triage test if these
would not detect EPTB but only test individuals with presump-
tive PTB and children with tuberculosis, such as for instance a
breath test); or
4. for the DST detection test, would be done after a more
sensitive tuberculosis detection test or be done in a staged ap-
proach only after rifampicin resistance is found (eg, after Xpert
MTB/RIF testing up-front). The different scenarios of each TPP
for which we determined the potential market size and value are
explained in Table 1. The method we describe and applied for
estimating and projecting the potential market size could be
used to estimate the potential market in other countries.
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RESULTS
In 2012 a total of 17 million individuals with presumptive
PTB were evaluated for the initial diagnosis of active tuber-
culosis using the current tests for detection available (smear
microscopy or Xpert) in the four countries (Table 2). We
estimated that approximately 46% of the individual with pre-
sumptive PTB were not tested (range between 12% and 57%
for the individual countries). Based on the country speciﬁc
Table 1. Base Case and Alternative Scenarios of the Target Product Proﬁles (TPPs) for Which the Potential Market is Determined
Scenario Description
TPP1: smear replacement
test
Base case Sputum-based smear replacement test, deployed at microscopy centers,
used for the initial diagnosis in individuals with presumptive PTB
Plus treatment monitoring Sputum-based smear replacement test, deployed at microscopy centers,
used for the initial diagnosis as well as for treatment monitoring in
individuals with PTB. Two additional tests were assumed per diagnosed
PTB case for treatment monitoring.
Low suspect-to case ratio Sputum-based smear replacement test, deployed at microscopy centers,
used for the initial diagnosis in individuals with presumptive PTB. A
‘suspect-to-case’ ratio of 5 was used to estimate the number of individuals
tested to find one PTB case instead of the country specific ratio.
High suspect-to-case ratio Sputum-based smear replacement test, deployed at microscopy centers,
used for the initial diagnosis in individuals with presumptive PTB. A
‘suspect-to-case’ ratio of 15 was used to estimate the number of
individuals tested to find one PTB case instead of the country specific
ratio.
TPP2: biomarker test Base case Non-sputum-based biomarker test, deployed at microscopy centers and
health-care clinics with a lab attached (equal to a 10% increase compared
to deployment at microscopy centers only), used for the initial diagnosis
in individuals with presumptive PTB, EPTB or children with tuberculosis.
Deployment at health posts Non-sputum-based biomarker test, deployed at health posts (without the
necessity of a lab), used for the initial diagnosis in individuals with
presumptive PTB, EPTB or children with tuberculosis. An increase of 20%
in the number of individuals that get tested was assumed compared to
when this test would only be deployed at microscopy centers.
Deployment at microscopy centers,
excluding EPTB testing
Non-sputum-based biomarker test, deployed at microscopy centers and
health-care clinics with a lab attached (equal to a 10% increase compared
to deployment at microscopy centers only), used for the initial diagnosis
in individuals with presumptive PTB or children with tuberculosis.
TPP3: triage test Base case Non-sputum-based triage test, deployed at health posts (20% increase in
number of individuals tested compared to use at a microscopy centre),
used to rule out tuberculosis in individuals with presumptive PTB, EPTB
or children with tuberculosis.
Sputum based test, deployment at
health posts
Sputum-based triage test, deployed at health posts (20% increase in
number of individuals tested compared to use at a microscopy centre),
used to rule out tuberculosis in individuals with presumptive PTB.
Non-sputum based test, deployment
at community
Non-sputum-based triage test, deployed at community care (30% increase
in number of individuals tested compared to use at a microscopy centre),
used to rule out tuberculosis in individuals with presumptive PTB, EPTB
or children with tuberculosis.
TPP 4A: tuberculosis
detection plus DST
upfront
Scenarios are equal to those
described for TPP1. This TPP is not
shown separately.
Sputum-based tuberculosis detection and DST in one, deployed at
microscopy centers, used for the initial diagnosis of PTB and drug
susceptibility testing of at least 1 drug in individuals with presumptive PTB.
TPP4B: DST after
tuberculosis
detection test
Base case, DST after tuberculosis
detection
Sputum-based DST, deployed at microscopy centers, used to test for drug
susceptibility in individuals who are diagnosed with PTB. An 80%
sensitivity was assumed for the diagnosis of PTB.
Increased sensitivity of PTB
detection (95%)
Sputum-based DST, deployed at microscopy centers, used to test for drug
susceptibility in individuals who are diagnosed with PTB. An increased
sensitivity of 95% was assumed for the diagnosis of PTB.
DST detection after detection of RIF
resistance
Sputum-based DST, deployed at microscopy centers, used to test for drug
susceptibility in individuals who are diagnosed with RIF resistant PTB. A
80% sensitivity was assumed for the diagnosis of PTB. Country-specific
prevalence of MDR tuberculosis was used as indicator for RIF resistance
prevalence.
Abbreviations: DST, drug susceptibility test; EPTB, extrapulmonary tuberculosis; MDR, multidrug resistant; PTB, pulmonary tuberculosis; RIF, rifampicin.
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Table 2. Key Variables and Assumptions per Country
Variable or
Assumption
South Africa Brazil China India Total
Source2012 2020 2012 2020 2012 2020 2012 2020 2012 2020
Prevalent
tuberculosis
cases
450 000 426 660 120 000 130 606 1 400 000 962 642 2 800 000 1 628 969 4 770 000 3 148 878 2012: WHO report 2013
2020: estimated based on
population size in 2020
according to World Bank
and estimated
tuberculosis prevalence
rate (using country
specific 3-year average
decline in tuberculosis
prevalence rate)
Percentage of all
prevalent
tuberculosis
patients that
have PTB
76% Same as
2012
78% Same as
2012
98% Same as
2012
72% Same as
2012
80% Same as
2012
WHO report 2013
Percentage of all
prevalent
tuberculosis
patients that
have EPTB
14% Same as
2012
14% Same as
2012
0.75% Same as
2012
20% Same as
2012
14% Same as
2012
WHO report 2013: % of
notified tuberculosis
cases with EPTB
Percentage of all
prevalent
tuberculosis
patients that are
children with
tuberculosis
(unable to
provide sputum)
10% Same as
2012
8% Same as
2012
1% Same as
2012
8% Same as
2012
6% Same as
2012
Calculation: notified smear-
positive tuberculosis
cases among children
assumed to represent 5%
of all children with
tuberculosis (personal
communication
A. Mandelakas and
B. Kampmann) and 85%
of children with
tuberculosis assumed to
be unable to produce
sputum.
Number of
individuals with
presumptive
tuberculosis
needed to test to
find one
tuberculosis
case (‘suspect to
case ratio’)
7 Same as
2012
15 Same as
2012
7 Same as
2012
9 Same as
2012
8.3a 8.6a Country specific ratio’s
obtained from NTPs or
data from NTPs
Estimated number
of individuals
with
presumptive
PTB
2 393 650 2 986 623 1 400 100 1 523 843 9 596 671 6 598 687 18 177 579 10 575 255 31 568 000 21 684 408 Calculation: (number of
prevalent PTB cases in
2012 multiplied by the
suspect-to-case-ratio)
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Table 2 continued.
Variable or
Assumption
South Africa Brazil China India Total
Source2012 2020 2012 2020 2012 2020 2012 2020 2012 2020
Number of
individuals with
presumptive
PTB suspects
tested in 2012
(in microscopy
centers)
2 116 667
(88% of
PTB
suspects)
88% of
PTB
suspects
965 544
(69% of
PTB
suspects)
69% of
PTB
suspects
6 173 936
(64% of
PTB
suspects)
64% of
PTB
suspects
7 867 194
(43% of PTB
suspects)
43% of PTB
suspects
17 123 341
(54% of PTB
suspects)
54% of PTB
suspects
Number of individuals tested
with smear and/or Xpert in
each country (data
provided by NTPs)
Number of
individuals with
presumptive
PTB not tested in
2012
276 983 12% of
PTB
suspects
434 556 31% of
PTB
suspects
3 422 735 36% of
PTB
suspects
10 310 385 57% of PTB
suspects
14 444 659 46% of PTB
suspects
Calculation: (number of
prevalent PTB cases in
2012 multiplied by
suspect-to-case-ratio) –
(tuberculosis suspects
tested in the public and
private sector in 2012)
Number of
individuals with
presumptive
EPTB (assumed
all not tested
in 2012)
441 000 418 127 252 000 274 272 73 500 50 539 5 040 000 2 932 144 5 806 500 3 675 082 Calculation: number of EPTB
cases in 2012 multiplied
by suspect-to-case ratio
Number of
children with
presumptive
tuberculosis
(unable to
provide sputum;
therefore
assumed not
tested in 2012)
315 350 298 994 147 900 160 972 129 829 89 271 1 982 421 1 153 322 2 575 500 1 702 559 Calculation: number of
children with tuberculosis,
unable to provide sputum
in 2012 multiplied by
suspect-to-case ratio
Total number of
individuals with
presumptive
tuberculosis
(PTB, EPTB and
children
combined) in the
country
3 150 000 2 986 623 1 800 000 1 959 087 9 800 000 6 738 496 25 200 000 14 660 721 39 950 000 26 344 927 Calculation: sum of number
of individuals with
presumptive PTB, EPTB
and children with
presumptive tuberculosis
(unable to provide
sputum)
Abbreviations: EPTB, extrapulmonary tuberculosis; NTP, national tuberculosis programmes; PTB, pulmonary tuberculosis; WHO, World Health Organization.
a Weighted averages.
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“suspect-to-case” ratio, which ranged between 7 in South Africa
and China up to 15 in Brazil, we estimated that an additional 5.8
million individuals with presumptive EPTB and another 2.6
million children with presumptive sputum-scarce tuberculosis
could have been evaluated in these countries in 2012.
The absolute number of prevalent tuberculosis cases is
expected to decline in the coming years in all 4 countries be-
cause the population growth rate is smaller than the decline
in the tuberculosis incidence rate. The total number of prevalent
cases in these 4 countries in 2020 was estimated to be around
3.1 million.
Potential Available Market for a Smear Replacement Test in
2020
For a novel smear replacement test with increased sensitivity for
the detection of PTB on sputum that can be deployed at micros-
copy centers with quick turnaround time, the potential market
size in 2020 was estimated at 2.0 million in South Africa, 1.1
million in Brazil, 4.3 million in China, and 4.6 million in
India. This amounts to a total of 12 million tests in that year
(Figure 1A). If the smear replacement test could also be used
for treatment monitoring and on average 2 additional tests
per diagnosed PTB case would be conducted during therapy, the
potential market size would grow to 15 million tests per year in
all four countries combined. Considering changes in the as-
sumed number of individuals that is tested in order to ﬁnd
one tuberculosis case (eg, lower or higher “suspect-to-case-
ratio”) the potential market size would vary between 7.7 million
(ratio of 5 in all countries) and 23 million tests (ratio of 15 in all
countries). The potential market value for a smear replacement
test under the base scenario will range between US$48 million
for a US$4 test up to US$71 million for a US$6 test in all 4 coun-
tries together (Figure 2).
Potential Available Market for a Biomarker Test in 2020
According to its TPP, a novel biomarker test that uses a non-
sputum based sample should ideally detect all forms of tubercu-
losis and be feasible to conduct at least in microscopy centers or
Figure 1. Potential available market (volume) for novel tuberculosis diagnostics in 2020 in 4 example countries. A, Smear replacement test (TPP 1 and
TPP 4A). B, Biomarker test (TPP 2). C, Triage test (TPP 3). D, drug susceptibility test (DST) after tuberculosis detection test (TPP 4B). Abbreviations: PTB,
pulmonary tuberculosis; RIF, rifampicin; TPP, target product proﬁle.
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health-care clinics with some form of a laboratory attached. Due
to its wider applicability, both in terms of target population and
in the number of facilities where the test can be conducted, the
PAM size in 2020 was estimated at 16.1 million tests for all 4
countries (Figure 1B). Obviously, the market size would in-
crease if the test could be deployed at lower levels of the
health-care system such as health posts without a laboratory
(total estimated at 17.6 million). On the other hand, if the bio-
marker test would not be able to diagnose EPTB but would de-
tect only PTB and tuberculosis in children, its market size
would be reduced by 13% compared to the base scenario
(total market size 14 million tests).
The potential market value for a biomarker test, for the base
case scenario, will range between US$65 million for a US$4 test
and US$97 million for a US$6 test in total in all 4 countries.
Potential Available Market for a Triage Test
A non-sputum based triage test that is easy to conduct at health
posts that do not have a laboratory attached and be used to rule
out tuberculosis in individuals with presumptive tuberculosis
could have a potential market size of 17.6 million tests in the
4 example countries combined (Figure 1C). In essence, the tri-
age test is expected to have about 10% larger market size than
the biomarker test because the test aims to reach difﬁcult to
reach populations that did not have access to tuberculosis test-
ing before. Although the potential market size for the TPPs de-
scribed here is largest for a triage test, its market value is lowest
(range between US$18 and US$35 million in total for all 4 coun-
tries under the base scenario) because the optimal price range
anticipated is US$1 to US$2 per test.
Potential Available Market for a DST in 2020
For a novel (sputum-based) rapid DST there are 2 possible op-
tions. First, the test can combine tuberculosis detection and
DST into one step (as in the case of Xpert) and test both for
the presence of Mycobacterium tuberculosis as for resistance
against at least one anti-tuberculosis drug in the same sample
and in the same test run. For such a test, the potential market
Figure 2. Potential available market (PAM) (value) for novel tuberculosis diagnostics in 2020 in 4 example countries. PAM in 2020 is presented for the
base case TPPs at their 2 price points. TPP1 shows the potential market value in 2020 for a TPP for a smear replacement test, deployed at microscopy
centers, used for the initial diagnosis of individuals with presumptive pulmonary tuberculosis, and at a price per test of US$4 and US$6. TPP2 shows the
potential market value in 2020 for a TPP for a biomarker based test, deployed at microscopy centers and health-care clinics with a lab, used for the initial
diagnosis of individuals with presumptive active tuberculosis (all forms), and at a price per test of US$4 and US$6. TPP3 shows the potential market value in
2020 for a TPP for a community triage test, deployed at health posts, used for the screening of individuals with presumptive active tuberculosis (all forms),
and at a price per test of US$1 and US$2. TPP4A shows the potential market value in 2020 for a TPP of a tuberculosis detection and drug susceptibility test
(DST) in one, deployed at microscopy centers, used for the detection of drug susceptibility in individuals with pulmonary tuberculosis, and at a price per test
of US$5 and US$20 for tuberculosis detection and DST combined. TPP4B shows the potential market value in 2020 for a TPP where the DST is conducted
after a positive tuberculosis detection. Both tests are deployed at microscopy centers, used for the detection of drug susceptibility in individuals with
pulmonary tuberculosis, and at a price of US$5 per tuberculosis detection test and US$10 or US$40 for the DST is assumed. Abbreviation: TPP, target
product proﬁle.
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size is equal to that of the smear replacement test (Figure 1A),
but because this test may cost slightly more, its potential market
value in 2020 in all 4 countries is estimated between US$59 and
US$238 million for a US$5 to US$20 test (Figure 2).
The second option is that DST only is done after a positive tu-
berculosis detection test. In this case, the potential market size
for the DST would be much smaller with a total of 252 000 tests
in South Africa, 70 000 in Brazil, 606 000 in China, and 616 000
in India (Figure 1D; a total of 1.5 million tests). Nevertheless,
the potential market value for both tuberculosis detection at
an average price of US$5 per test followed by DST (at least
one drug but preferably more ﬁrst-line drugs) at a price range
between US$10 and US$40 for DST would amount between US
$75 million and US$121 million (Figure 2).
DISCUSSION
In this study, we described the PAM in 2020 for 4 novel diagnos-
tics that meet the speciﬁcation outlined in the TPPs described
elsewhere in this supplement [4, 5]. This PAM was determined
both in size and in value for 4 countries (South Africa, Brazil,
China, and India) that have a high tuberculosis burden but
also are emerging economies that can invest in the implementa-
tion and rollout of new, modern technologies that have the po-
tential to lead to increased testing and enhanced case detection
and which are therefore of interest for test developers.
Product developers need data on issues such as potential
global market size, the potential country speciﬁc market size,
and return on investment, but such information is often lack-
ing (D. Dolinger, FIND, personal communication) [6]. We
showed a general approach for estimating the PAM for novel
products when used in their intended target population and
at their intended level of the health-care system, which can be
adapted for other countries or for other assumptions.
Our results indicate that, of the 4 TPPs, the greatest PAM in
terms of value would be for a (sputum-based) tuberculosis de-
tection and DST upfront test although this is mainly a result of
the high cost per test that we assumed (up to US$20). Such a
test, essentially, would be a more sensitive “Xpert”-like test
that not only tests for the presence ofM. tuberculosis and rifam-
picin resistance but also resistance against additional drugs. Al-
though the potential market looks promising, it is questionable
if such a test would be affordable for all countries at this price
point [10]. Cost-effectiveness studies on an individual country
level are recommended which can take the local epidemiology
(eg, prevalence of MDR-tuberculosis) and current testing algo-
rithms in place into account to assess which test strategies are
most effective and least costly. Tests that can be deployed at
lower levels of the health-care system and which could be
used for the detection (or rule-out) of all forms of tuberculosis,
such as a biomarker test or a triage test would have the largest
potential market volume. And a triage test algorithm might
even be cost-effective even at an even higher price point than
what we have used here [13].
In this study, we determined the total PAM for novel tests
under the assumption that these would be implemented through-
out the whole country and cover 100% of the intended health-
care facilities. When different products will reach the market
that ﬁt within the same TPP, obviously these products would
compete for a share of the same potential available market. Prod-
ucts that meet more of the criteria listed under the “optimal” sce-
nario of the TPPs might account for a larger market share.
In addition, there is interplay between the different TPPs. Al-
though the tuberculosis community has expressed a need for
each of the TPPs, and there will be a market for each of them,
there is potential overlap in the target populations of some of
the tests. Although a triage test and rapid DST are unlikely to
compete, a biomarker test for instance will likely replace a
smear-replacement test. As a result, there may not only be com-
petition for products that ﬁt the same TPP, but competition
could also occur between products that meet different TPPs.
The time that novel products will enter the market, the strength
of evidence on the test, the recommended use by national and
international guidelines of these products in global or local di-
agnostics algorithms, but also the local epidemiology and pref-
erences will therefore greatly determine the actual market size
and penetration.
Several limitations should be taken into consideration when
interpreting our results. First, one of the main assumptions in
our analysis was the country-speciﬁc “suspect-to-case” ratio.
Upon changes in this ratio either to a higher or lower number
the estimated market size and consequently its volume ﬂuctuat-
ed considerably (−35% or +96% when all 4 countries were com-
bined). Although we determined country speciﬁc ratios, these
were based on the number of individuals with presumptive
PTB tested in order to ﬁnd one PTB case and were assumed
to be equal for EPTB and children with tuberculosis (unable
to provide sputum), which might not be true. Moreover, we as-
sumed that this ratio would remain constant and not change
when tests would be applied at lower levels of the health-care
system, while in fact this ratio is likely to increase over time
when the prevalence decreases.
In our estimates we used the prevalence estimates according
to the WHO. Although these estimates are yearly updated and
reﬁned, there is uncertainty around the precise prevalence rates
and therefore also the estimates that we presented here for the
potential market size for novel test.
Another limitation is that we assumed that an additional
10%, 20%, and even 30% of individuals would get tested
when a test would be conducted in health-care clinics with a
lab attached, health posts, or in the community besides its use
in microscopy centers. Although we did not have accurate data
to underpin this assumption, a study conducted by Girosi and
Olmsted et al in 2006 estimated that up to 25% of the
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population in Africa had access to facilities with no infrastruc-
ture, 47% to infrastructure with minimal infrastructure, and
28% to facilities with moderate to advanced infrastructure
[14, 15]. Finally, there is uncertainty around the prices of
novel tests. The prices used in our calculations should be con-
sidered purely indicative as it is hard to predict real prices
(which are based on donor investments, special pricing and ac-
cess agreements, volume-based discounts, etc.).
By 2020, it is highly like that new tuberculosis drug regimens
will be available. Because newer drug regimens are critically de-
pendent on companion diagnostics for scale-up, there are ongo-
ing efforts to achieve convergence between diagnostics and new
drug regimens [16]. The introduction of newer regimens is not
expected to affect the PAM estimates outlined here, unless these
will affect current testing practices and for instance lead to an
increase in testing during treatment.
In conclusion, we showed that there is a great PAM in the 4
example high-burden countries for novel diagnostics such as a
smear replacement test, a biomarker test, a triage test, and DST
when these would meet the speciﬁcations outlined in the TPPs.
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